GH Optimization Protocol
Maximize natural growth hormone output for recovery, body composition, and anti-ageing
Peptide Stack
Preparation
Reconstitute both peptides with bacteriostatic water. CJC-1295 (no DAC) and Ipamorelin can be mixed in the same syringe for convenience. Store at 2-8°C and use within 2-4 weeks.
Administration
Inject subcutaneously three times daily: morning (fasted), post-workout, and before bed. Always administer on an empty stomach (2 hours after eating, 20 minutes before eating) for optimal GH release. Rotate injection sites.
Monitoring
Track sleep quality, recovery time, body composition changes, and energy levels weekly. Many users report improved sleep within 1-2 weeks. Body composition changes typically visible by week 4-6.
Expected Timeline
Week 1-2: Improved sleep quality and recovery. Week 3-6: Enhanced body composition, increased lean mass. Week 7-12: Continued improvements in recovery, skin quality, and overall vitality. Effects amplify with consistent use.
Research Basis
CJC-1295 (no DAC) is a GHRH analogue that stimulates GH release from the pituitary. Ipamorelin is a selective ghrelin receptor agonist. Together, they work synergistically on separate pathways to amplify GH pulses 2-3x beyond either alone, without significantly affecting cortisol or prolactin.
Safety Considerations
- Do not use if you have active cancer
- Avoid during pregnancy or breastfeeding
- May cause temporary water retention or joint discomfort
- Monitor blood glucose if diabetic
- Consult with a healthcare professional before starting
- This protocol is for research and educational purposes only
Protocol Overview
Maximize natural growth hormone output using the synergistic GHRH + GHRP combination. CJC-1295 (no DAC) and Ipamorelin work on separate receptor pathways to amplify GH pulses 2-3x beyond either alone.
Duration: 12 weeks Peptides: 2 Experience Level: Beginner
Peptide Stack
CJC-1295-NO-DAC
- Dose: 100 mcg
- Frequency: three times daily
- Timing: morning, post-workout, and before bed
IPAMORELIN
- Dose: 100-200 mcg
- Frequency: three times daily
- Timing: with CJC-1295 doses
Preparation
Reconstitute both peptides with bacteriostatic water. CJC-1295 (no DAC) and Ipamorelin can be mixed in the same syringe for convenience. Store at 2-8°C and use within 2-4 weeks.
Administration
Inject subcutaneously three times daily: morning (fasted), post-workout, and before bed. Always administer on an empty stomach (2 hours after eating, 20 minutes before eating) for optimal GH release. Rotate injection sites.
Monitoring
Track sleep quality, recovery time, body composition changes, and energy levels weekly. Many users report improved sleep within 1-2 weeks. Body composition changes typically visible by week 4-6.
Expected Timeline
Week 1-2: Improved sleep quality and recovery. Week 3-6: Enhanced body composition, increased lean mass. Week 7-12: Continued improvements in recovery, skin quality, and overall vitality. Effects amplify with consistent use.
Research Basis
CJC-1295 (no DAC) is a GHRH analogue that stimulates GH release from the pituitary. Ipamorelin is a selective ghrelin receptor agonist. Together, they work synergistically on separate pathways to amplify GH pulses 2-3x beyond either alone, without significantly affecting cortisol or prolactin.
Safety Considerations
- Do not use if you have active cancer
- Avoid during pregnancy or breastfeeding
- May cause temporary water retention or joint discomfort
- Monitor blood glucose if diabetic
- Consult with a healthcare professional before starting
- This protocol is for research and educational purposes only
Disclaimer: This protocol is for educational and research purposes only. It is not medical advice. Consult with a qualified healthcare professional before starting any peptide protocol. These compounds are not approved by the MHRA for human therapeutic use.
Important Disclaimer: This protocol is for educational and research purposes only. It is not medical advice. Consult with a qualified healthcare professional before starting any peptide protocol. These compounds are not approved by the MHRA for human therapeutic use.